What results hip patients can realistically expect

Roughly four in five suitably selected patients see good or excellent cartilage healing outcomes at three to five years — a figure drawn from the strongest available hip-specific cohort, in which 17 of 21 evaluable adults (81%) met that threshold following ChondroFiller treatment (Mazek, Journal of Hip Preservation Surgery, 2021). Across the broader published evidence base, which spans knee and small-joint studies and informs the hip pathway by shared scaffold biology, 70–85% of treated patients report meaningful symptom relief at the same timeframe, with patient satisfaction sitting at approximately 80%.

In practice, 'meaningful improvement' translates to real-world gains in hip mobility and pain reduction, not merely an improved scan. Published data indicate functional score improvements of roughly 30 points — well above the threshold considered clinically significant — alongside MRI evidence of defect filling and progressive scaffold integration over the first twelve months.

These headline figures apply to well-selected candidates. Outcomes are directly linked to lesion characteristics, joint status, and the thoroughness of pre-treatment assessment; they do not apply uniformly to every presentation of hip pain.

At MSK Doctors, ChondroFiller is delivered as an ultrasound-guided outpatient injection — not a surgical procedure. Patients are assessed by a consultant before treatment to confirm whether their cartilage profile and joint status make them suitable for this pathway.

How the injectable collagen scaffold works

Unlike viscosupplementation or anti-inflammatory injections, ChondroFiller does not simply coat the joint or dampen pain signals — it provides a structural template intended to prompt the body's own repair activity.

The product is an acellular Type I collagen scaffold: it contains no living cells. Delivered under ultrasound guidance as a liquid, it gels in situ within the joint within minutes of placement, conforming to the contours of the cartilage defect. Once in place, the scaffold undergoes what clinicians describe as acellular matrix-induced chondrogenesis — in plain terms, the collagen matrix acts as a chemotactic signal, drawing the patient's own progenitor cells from the surrounding synovium and subchondral bone into the defect, where they begin differentiating towards cartilage-forming cells. The treatment supports the body's own repair processes rather than delivering ready-made tissue.

This separates it clearly from two commonly compared options. Hyaluronic acid (viscosupplementation) improves joint lubrication but does not support tissue repair. Corticosteroid injections reduce inflammation in the short term but have no regenerative effect on cartilage structure.

Structural change through the scaffold is gradual. MRI studies show maturation progressing from four weeks through to twelve months after injection — patients should not expect an immediate structural result, and follow-up imaging at around one year is the realistic point at which integration becomes visible.

ChondroFiller is CE-marked as a Class III medical device and is in wide clinical use across Europe and the UK. It is not approved by the FDA for use in the United States.

The clinical evidence behind hip-specific outcomes

The 81% good-or-excellent result cited earlier comes from a single prospective study — the Mazek 2021 cohort of 26 adults — and that is both the strength and the honest limitation of the hip-specific evidence base. There is, as yet, no randomised controlled trial for ChondroFiller in the hip, and that context matters when weighing what the numbers represent.

That prospective dataset is supplemented, rather than replaced, by two further bodies of evidence. First, structural MRI data from broader ChondroFiller studies record MOCART scores — a standardised scale rating cartilage repair quality out of 100 — of 81.6 to 84.3, corresponding to more than 80% defect filling and good integration with surrounding native cartilage. Second, IKDC scores (a validated patient-reported function measure out of 100 used widely in joint research) improve by roughly 30 points in published ChondroFiller series. The threshold considered a meaningful change is 16.7 points, so a 30-point gain represents clearly significant functional recovery. These functional data derive primarily from knee studies; hip-specific patient-reported outcome data at comparable scale have not yet been published.

Post-market surveillance provides real-world context across all joints and delivery routes: more than 19,000 cases logged since 2013 record no serious adverse device effects and a complaint rate of approximately 0.06%.

The best available hip data come from one study of 26 people; robust trials are still to come. For the injectable route specifically, independent published outcome data in the hip do not yet exist. That does not disqualify the treatment — it reflects where a specialised scaffold pathway sits in its evidence journey, and the prospective data that do exist are consistently encouraging.

The patient profile that predicts the best results

Suitability turns on two variables above all others: the pattern of cartilage loss and the degree of underlying osteoarthritis — and the answer differs depending on which treatment pathway is being considered.

Patients who tend to do best with ChondroFiller are those with focal, contained cartilage defects rather than diffuse, joint-wide degeneration. In the Mazek 2021 hip cohort, all treated lesions exceeded 2 cm² in area — suggesting the scaffold is best matched to substantive but localised damage rather than surface-level wear. Alongside defect morphology, consultants weigh activity level, the absence of significant mechanical malalignment, and overall joint status on imaging.

The Tönnis grading threshold

For the arthroscopic surgical route, the most decisive contraindication in the hip data is pre-existing osteoarthritis graded Tönnis 2 or 3. In the Mazek cohort, patients at these grades consistently achieved poor results — making this the clearest patient-selection signal the hip evidence currently provides. Tönnis grade 0 or 1 at presentation is the profile associated with favourable outcomes.

The injectable pathway and broader candidacy

The ultrasound-guided injectable route operates under different criteria. Because the treatment acts as an additive collagen scaffold rather than a surgically implanted defect filler, it can be appropriate for patients with more diffuse wear — including those with Kellgren-Lawrence Grade III or IV changes — where the surgical cohort data would not apply. There is no categorical age ceiling, and bone-on-bone status alone does not automatically exclude patients from assessment.

Active inflammatory arthritis, joint infection, or systemic conditions that impair healing typically place patients outside the suitable group for either pathway. The MSK Doctors team establishes suitability through clinical assessment and imaging review — no GP referral is needed to begin that conversation.

Safety record and what to expect after the injection

The safety record established across more than a decade of real-world use translates, in practice, to a predictable and manageable experience for most patients.

In the first 72 hours after an ultrasound-guided ChondroFiller injection, localised swelling, a temporary pain flare, and joint stiffness are the reactions most commonly reported. These mirror the response to any intra-articular injection and settle without intervention within a few days; no specific aftercare is typically required beyond a short period of reduced loading.

Because ChondroFiller at MSK Doctors is delivered as an outpatient injection, there is no general anaesthetic, no hospital admission, and no surgical wound to manage. Patients leave the clinic the same day.

On a longer horizon, a small proportion of patients — between 3 and 8% in post-market surveillance data — go on to need a further procedure. That figure sits substantially below reoperation rates associated with surgical cartilage repair alternatives, which provides useful context when comparing pathways.

Symptom change is gradual rather than immediate. The scaffold takes time to integrate and for the body's own repair activity to gather pace; patients who calibrate their expectations to weeks and months rather than days are better placed to assess progress accurately.

Getting assessed at MSK Doctors without a referral

A first appointment at MSK Doctors does not require a GP referral or an NHS waiting-list place — patients can book directly at a time that suits them. The assessment itself is a single consultant-led session covering clinical history, a review of any existing imaging, and arrangement of MRI where indicated. Crucially, it includes a frank discussion of whether ChondroFiller is the appropriate fit given the patient's specific hip picture — the lesion pattern, degree of osteoarthritis, and wider health status — rather than a default recommendation in either direction.

For patients in Lincolnshire and the wider non-London catchment, the primary assessment sites are the Regeneration Hub in Sleaford (NG34), which houses an Open MRI scanner, and the Grantham diagnostics and consultation centre (NG31). London-based patients can access the same consultant-led pathway through the London Cartilage Clinic.

MSK Doctors is CQC-registered and rated Good across all five inspection domains. To arrange an assessment, visit mskdoctors.com.